What GLP-1 Actually Is
GLP-1 stands for glucagon-like peptide-1. It is a hormone your body naturally produces in your gut after you eat. When food reaches your intestines, specialized cells release GLP-1 into your bloodstream. This hormone does several important things simultaneously.
First, GLP-1 signals your pancreas to release more insulin, but only when your blood sugar is elevated. This is important because it means the hormone helps lower blood sugar without pushing it dangerously low. Second, GLP-1 slows down gastric emptying, meaning food stays in your stomach longer. This is why you feel full for a longer period after eating. Third, GLP-1 acts on appetite centers in your brain, specifically the hypothalamus, reducing hunger signals and food cravings.
In a healthy person, natural GLP-1 is broken down by an enzyme called DPP-4 within about two minutes. It does its job and disappears quickly. The breakthrough of drugs like semaglutide, the active ingredient in Ozempic and Wegovy, is that they are engineered to resist this breakdown. A single injection of semaglutide stays active in your body for about a week, providing continuous appetite suppression and blood sugar control that natural GLP-1 simply cannot.
How These Drugs Work for Diabetes
Ozempic was originally developed and approved for type 2 diabetes, and it remains one of the most effective diabetes medications available. In clinical trials, semaglutide reduced A1C levels by 1.5 to 1.8 percentage points on average, which is a substantial improvement. For context, bringing your A1C down by just one point reduces your risk of diabetes-related complications, including eye disease, kidney disease, and nerve damage, by roughly 25 to 40 percent.
Beyond blood sugar control, semaglutide has shown remarkable cardiovascular benefits. The SELECT trial demonstrated a 20 percent reduction in major cardiovascular events, including heart attacks, strokes, and cardiovascular death, in patients taking semaglutide compared to placebo. This was true even in patients who did not have diabetes. These cardiovascular benefits are one of the reasons the medical community has embraced these drugs so enthusiastically.
For patients with type 2 diabetes who also carry excess weight, GLP-1 drugs address both problems simultaneously. The weight loss improves insulin sensitivity, which further improves blood sugar control, creating a positive cycle that many older diabetes medications could not achieve.
How They Work for Weight Loss
Wegovy is the brand name for a higher dose of semaglutide specifically approved for weight management. In the STEP clinical trials, patients taking Wegovy lost an average of 15 to 17 percent of their body weight over 68 weeks. For a person weighing 220 pounds, that is roughly 33 to 37 pounds. Some patients lost significantly more.
The weight loss comes from multiple mechanisms working together. The drug reduces appetite by acting on brain regions that control hunger and food reward. Patients consistently report that food simply becomes less interesting. Cravings diminish. The constant mental noise about eating that many people with obesity experience goes quiet. At the same time, the slowed gastric emptying means you feel physically full after eating smaller portions.
Tirzepatide, sold as Mounjaro for diabetes and Zepbound for weight loss, works on both GLP-1 and GIP receptors, another gut hormone. In clinical trials, tirzepatide produced even greater weight loss, with some patients losing over 20 percent of their body weight. These results are approaching what was previously only achievable through bariatric surgery.
It is important to understand that these drugs are most effective when combined with lifestyle changes. Diet modification and regular physical activity enhance the results and help maintain the weight loss long term. The medication is a powerful tool, but it works best as part of a comprehensive approach.
Side Effects You Need to Know About
The most common side effects are gastrointestinal. Nausea is the most frequently reported, affecting roughly 20 to 40 percent of patients, particularly during the dose escalation phase when the medication is gradually increased. Vomiting, diarrhea, constipation, and abdominal pain also occur. For most patients, these symptoms are mild to moderate and improve after the first few weeks as the body adjusts.
The dose escalation schedule exists precisely to minimize these effects. Starting at a low dose and gradually increasing it over several weeks gives your body time to adapt. Eating smaller meals, avoiding high-fat and greasy foods, and eating slowly can also help manage nausea.
More serious but less common risks include pancreatitis, inflammation of the pancreas that causes severe abdominal pain. Patients should be aware of this symptom and seek medical attention immediately if it occurs. There is also a boxed warning about thyroid tumors, based on animal studies showing an increased risk of a specific type of thyroid cancer called medullary thyroid carcinoma. This has not been confirmed in humans, but the drugs are not recommended for patients with a personal or family history of this cancer or a condition called Multiple Endocrine Neoplasia syndrome type 2.
Gallbladder problems, including gallstones, have been reported at higher rates in patients taking GLP-1 drugs, likely related to rapid weight loss. Rapid weight loss from any cause increases gallstone risk. There have also been reports of gastroparesis-like symptoms, where gastric emptying slows so much that patients experience persistent nausea, vomiting, and stomach pain. If this occurs, the dose may need to be reduced or the medication stopped.
What Happens When You Stop Taking Them
This is one of the most important and honest conversations to have about GLP-1 drugs. Studies consistently show that most patients regain a significant portion of the weight they lost within one to two years of stopping the medication. In the STEP 1 extension trial, patients who stopped semaglutide regained about two-thirds of their lost weight within a year.
This is not a failure of the patient. Obesity is a chronic disease driven by hormonal, genetic, and neurological factors. When you stop the medication, the biological drivers of weight gain, including increased appetite and metabolic adaptation, return. This is similar to how blood pressure rises again when you stop taking blood pressure medication. The medication manages the condition; it does not cure it.
This reality means that for many patients, GLP-1 drugs may need to be taken long-term, potentially for life. This raises important questions about cost, insurance coverage, and long-term safety data that are still being studied. Having an open conversation with your doctor about long-term planning is essential before starting these medications.
Who Should and Should Not Take These Drugs
GLP-1 drugs are approved for adults with type 2 diabetes and for weight management in adults with a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related health condition such as high blood pressure, type 2 diabetes, or high cholesterol.
They are not appropriate for everyone. People with a personal or family history of medullary thyroid carcinoma or MEN2 should not take them. People with a history of pancreatitis should use them with caution. They should not be used during pregnancy or while breastfeeding. They are not currently approved for children under 12 for weight management, though studies are underway.
These medications should be prescribed by a healthcare provider who can evaluate your complete medical history, monitor your progress, and adjust your treatment as needed. They are not cosmetic weight loss drugs for people who want to lose a few vanity pounds. They are medical treatments for serious metabolic conditions. Using them responsibly, with proper medical supervision, is essential for safety and effectiveness.
